Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended September 30, 2002, for Corniche Group Incorporated. The registrant previously operated an internet-based extended warranty and service contract business (warrantysuperstore.com) but became inactive effective June 30, 2002. Management is currently exploring a strategic pivot into the biotechnology and medical device sectors, though no new business has been acquired. The company is in a shell status, relying on cash reserves and the recovery of a defaulted loan to fund operations.
Key Financial Metrics
| Metric | Three Months Ended Sept 30, 2002 | Nine Months Ended Sept 30, 2002 | Balance Sheet (Sept 30, 2002) |
|---|---|---|---|
| Revenue | $19,986 | $62,825 | - |
| Net Loss (Attributable to Common) | $(230,962) | $(819,202) | - |
| Cash and Equivalents | - | - | $50,043 |
| Total Current Assets | - | - | $1,353,880 |
| Total Current Liabilities | - | - | $1,049,313 |
| Stockholders' Equity (Deficit) | - | - | $(444,402) |
| Notes Receivable (StrandTek) | - | - | $1,250,000 |
| Preferred Dividends Payable | - | - | $373,590 |
Note: The company reported a gross profit of $5,809 for the quarter and $15,584 for the nine-month period. Operating losses were driven by SG&A expenses of $230,770 (quarter) and $807,731 (nine months).
Material Changes vs. Prior Period
- Revenue Decline: Revenue for the three months ended September 30, 2002, decreased to $19,986 from $32,866 in the prior year period. Nine-month revenue was flat at $62,825 compared to $65,090 in 2001. Current revenue is derived entirely from the amortization of deferred contracts sold in prior periods.
- Expense Reduction: Selling, general, and administrative (SG&A) expenses decreased 40.2% year-over-year for the quarter ($230,770 vs. $387,360) and 30.9% for the nine months ($807,731 vs. $1,168,848). This reduction is attributed to the winding down of operations and office closures in July 2002, despite incurring $143,000 in one-time termination and closure costs.
- Asset Liquidation: The company sold all property and equipment (excluding software) in July 2002 and recorded an impairment charge of $54,732. Marketable securities held at year-end 2001 ($1.5 million) were liquidated during the period.
- Loan Default: A $1.25 million note receivable from StrandTek International, Inc., due July 31, 2002, was not repaid. The company ceased accruing interest on this note as of the due date.
Outlook, Risks, and Contingencies
- Strategic Pivot: Management is in discussions with a group to transition the company into the biotech/medical sector. This strategy requires raising new capital and recruiting personnel. There is no assurance that a new business will be acquired or that financing will be obtained.
- Liquidity Risk: With cash balances of only $50,043 and a working capital deficit, the company relies on short-term borrowings ($231,000 raised in the period) and the potential recovery of the $1.25 million StrandTek loan to fund operations.
- Legal Proceedings: The company filed a lawsuit against StrandTek and its guarantors to recover the defaulted loan. Defendants have filed counterclaims disputing the debt's validity. The outcome is uncertain.
- Preferred Stock Obligations: The company has $373,590 in accrued dividends payable on Series A preferred stock. Redemption of these shares is contingent on the company having legal funds available, which is currently constrained.
Investor Verification Checklist
- Verify the status of the litigation against StrandTek International, Inc. regarding the $1.25 million defaulted note.
- Confirm the company's ability to meet its $373,590 preferred dividend obligation and the terms of its $125,000 in new short-term notes payable (15% interest).
- Assess the progress of the proposed biotech/medical sector acquisition and the likelihood of securing necessary capital.
- Review the company's cash burn rate given the minimal cash balance ($50,043) and lack of operating revenue.